Citation: | ZHANG Bingsen, ZHAO Ze’an, LI Yongmei, et al. Anti-hyperuricemic and Anti-gout Effects of Olive Juice Freeze Dried Powder in Rats[J]. Science and Technology of Food Industry, 2021, 42(24): 347−353. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021030330. |
[1] |
SO A K, MARTINON F. Inflammation in gout: Mechanisms and therapeutic targets[J]. Nature Reviews Rheumatol,2017,13(11):639−647. doi: 10.1038/nrrheum.2017.155
|
[2] |
DESAI J, STEIGER S, ANDERS H. Molecular pathophysiology of gout[J]. Trends in Molecular Medicine,2017,23(8):756−768. doi: 10.1016/j.molmed.2017.06.005
|
[3] |
VARGAS SANTOS A B, NEOGI T. Management of gout and hyperuricemia in CKD[J]. American Journal of Kidney Diseases,2017,70(3):422−439. doi: 10.1053/j.ajkd.2017.01.055
|
[4] |
BALL G V, SORENSEN L B. Pathogenesis of hyperuricemia in saturinine gout[J]. New England Journal of Medicine,1969,280(22):1199−1202. doi: 10.1056/NEJM196905292802203
|
[5] |
SAKURAI H. Urate transporters in the genomic era[J]. Current Opinion Nephrology and Hypertension,2013,22(5):545−550. doi: 10.1097/MNH.0b013e328363ffc8
|
[6] |
张凯, 付冰冰, 孙晓鹏. 尿酸分泌相关转运蛋白研究进展[J]. 中国医药科学,2020,10(14):40−43. [ZHANG K, FU B B, SUN X P. Research progress of uric acid secretion related transporters[J]. China Medicine and Pharmacy,2020,10(14):40−43. doi: 10.3969/j.issn.2095-0616.2020.14.011
|
[7] |
ZHAO Z, JIANG Y, LI L, et al. Structural insights into the atomistic mechanisms of uric acid recognition and translocation of human urate anion transporter 1[J]. ACS Omega,2020,5(51):33421−33432. doi: 10.1021/acsomega.0c05360
|
[8] |
ANZAI N, JUTABHA P, AMONPATUMRAT TAKAHASHI S, et al. Recent advances in renal urate transport: Characterization of candidate transporters indicated by genome-wide association studies[J]. Clinical and Experimental Nephrology,2012,16(1):89−95. doi: 10.1007/s10157-011-0532-z
|
[9] |
HOSOYAMADA M, SHIBASAKI T, ICHIDA K. Molecular mechanism in biological transport in the kidney: Urate transporter URAT1[J]. Japanese Journal of Clinical Medicine,2006,64(Suppl2):176−179.
|
[10] |
RICHETTE P, BARDIN T. Gout[J]. Lancet,2010,375(9711):318−328. doi: 10.1016/S0140-6736(09)60883-7
|
[11] |
WU X H, WANG C Z, WANG S Q, et al. Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine[J]. Journal of Ethnopharmacology,2015,162:362−368. doi: 10.1016/j.jep.2015.01.012
|
[12] |
KANBAY M, SOLAK Y, GAIPOV A, et al. Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent: Hype or reality?[J]. Blood Purification,2014,37(3):172−178. doi: 10.1159/000360520
|
[13] |
CHEN Y, ZHAO Z, LI Y, et al. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase[J]. Phytomedicine,2021,80:153374−153382. doi: 10.1016/j.phymed.2020.153374
|
[14] |
吴美音, 陈淑宁, 高洁, 等. 菊苣、葛根、桑叶配方对高尿酸合并关节炎小鼠的降尿酸和痛风性关节炎的干预效果[J]. 食品工业科技,2020,41(16):308−313. [WU M Y, CHEN S N, GAO J, et al. Intervention effects of chicory, pueraria and mulberry leaf formula on reducing uric acid and gouty arthritis in mice with high uric acid and arthritis[J]. Science and Technology of Food Industry,2020,41(16):308−313.
|
[15] |
于建伟, 王桐, 董丛超, 等. 青梅提取物改善痛风和高尿酸血症的研究[J]. 食品工业科技,2014,35(17):351−353. [YU J W, WANG T, DONG C C, et al. Study on the improvement of Prunus mume extracts for the gout and hyperuricemia[J]. Science and Technology of Food Industry,2014,35(17):351−353.
|
[16] |
谭明亮, 陈刚. 茶多酚对高尿酸血症小鼠尿酸水平的影响及机制研究[J]. 食品工业科技,2015,36(12):349−352. [TAN M L, CHEN G. Study on effect and mechanism of tea polyphenols on serum uric acid in hyperuricemic mice[J]. Science and Technology of Food Industry,2015,36(12):349−352.
|
[17] |
LI R, YU K, LI C. Dietary factors and risk of gout and hyperuricemia: A meta-analysis and systematic review[J]. Asia Pacific Journal of Clinical Nutrition,2018,27(6):1344−1356.
|
[18] |
ZHANG M Y, NIU J Q, WEN X Y, et al. Liver failure associated with benzbromarone: A case report and review of the literature[J]. World Journal of Clinical Cases,2019,7(13):1717−1725. doi: 10.12998/wjcc.v7.i13.1717
|
[19] |
REBOREDO RODRÍGUEZ P, VARELA-LÓPEZ A, FORBES HERNÁNDEZ T Y, et al. Phenolic compounds isolated from olive oil as nutraceutical tools for the prevention and management of cancer and cardiovascular diseases[J]. International Journal of Molecular Sciences,2018,19(8):2305−2325. doi: 10.3390/ijms19082305
|
[20] |
SERRELI G, DEIANA M. Extra virgin olive oil polyphenols: Modulation of cellular pathways related to oxidant species and inflammation in aging[J]. Cells,2020,9(2):478−498. doi: 10.3390/cells9020478
|
[21] |
MEHMOOD A, ZHAO L, WANG C, et al. Management of hyperuricemia through dietary polyphenols as a natural medicament: A comprehensive review[J]. Critical Reviews in Food Science and Nutrition,2019,59(9):1433−1455. doi: 10.1080/10408398.2017.1412939
|
[22] |
MEHMOOD A, ZHAO L, WANG C, et al. Stevia residue extract alone and combination with allopurinol attenuate hyperuricemia in fructose-PO-induced hyperuricemic mice[J]. Journal of Food Biochemistry,2020,44(1):13087−13107.
|
[23] |
吴婷, 赵泽安, 陈演瑜, 等. 大麦叶粉防治高尿酸血症及肾脏保护作用研究[J]. 食品工业科技,2020,41(22):294−298,304. [WU T, ZHAO Z A, CHEN Y Y, et al. Anti-hyperuricemic and nephroprotective effects of barley leaf powder in hyperuricemic mice[J]. Science and Technology of Food Industry,2020,41(22):294−298,304.
|
[24] |
陈嘉盛, 吴婷, 丘玉昌, 等. 以hURAT1为靶点的排尿酸药物体外细胞筛选模型的建立和应用[J]. 生命科学研究,2016,20(3):248−254. [CHEN J S, WU T, QIU Y C, et al. A cell line stably expressing lentivirus-mediated hURAT1 as an in vitro model of screening uricosuric agents[J]. Life Science Research,2016,20(3):248−254.
|
[25] |
ZHAO Z A, JIANG Y, CHEN Y Y, et al. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia[J]. Acta Pharmacologica Sinica,2021,10:1−12.
|
[26] |
ICHIDA K, MATSUO H, TAKADA T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia[J]. Nature Communication,2012,3:764−770. doi: 10.1038/ncomms1756
|
[27] |
THURSTON M M, PHILLIPS B B, BOURG C A. Safety and efficacy of allopurinol in chronic kidney disease[J]. Annals of Pharmacotherapy,2013,47(11):1507−1516. doi: 10.1177/1060028013504740
|
[28] |
WANG W, PANG J, HA E H, et al. Development of novel NLRP3-XOD dual inhibitors for the treatment of gout[J]. Bioorganic & Medicinal Chemistry Letters,2020,30(4):126944−126948.
|
[29] |
ZHENG S C, ZHU X X, XUE Y, et al. Role of the NLRP3 inflammasome in the transient release of IL-1β induced by monosodium urate crystals in human fibroblast-like synoviocytes[J]. Journal of Inflammation,2015,12(1):30−38. doi: 10.1186/s12950-015-0070-7
|
[30] |
BEN B S, KELEBEK H, AMMAR S, et al. LC-MS phenolic profiling combined with multivariate analysis as an approach for the characterization of extra virgin olive oils of four rare tunisian cultivars during ripening[J]. Food Chemistry,2017,229:9−19. doi: 10.1016/j.foodchem.2017.02.025
|
[31] |
PINHO I A, LOPES D V, MARTINS R C, et al. Phytotoxicity assessment of olive mill solid wastes and the influence of phenolic compounds[J]. Chemosphere,2017,185:258−267. doi: 10.1016/j.chemosphere.2017.07.002
|
[32] |
李桂美. 痛风的饮食治疗与自我管理[J]. 家庭科技,2020(6):57−58. [LI G M. Diet therapy and self-management of gout[J]. Jia Ting Ke Ji,2020(6):57−58. doi: 10.3969/j.issn.1005-7293.2020.06.025
|
[33] |
杜妍妍, 赵绮华, 邵剑, 等. 高尿酸血症的营养治疗新进展[J]. 现代预防医学,2020,47(6):1145−1147,1152. [DU Y Y, ZHAO Q H, SHAO J, et al. The new progress in nutritional therapy of hyperuricemia[J]. Modern Preventive Medicine,2020,47(6):1145−1147,1152.
|
[34] |
CUI D, LIU S, TANG M, et al. Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption[J]. Phytomedicine,2020,66:153111−153120. doi: 10.1016/j.phymed.2019.153111
|
[35] |
ZHAO T, MENG Q, SUN Z, et al. Novel human urate transporter 1 inhibitors as hypouricemic drug candidates with favorable druggability[J]. Journal of Medicinal Chemistry,2020,63(19):10829−10854. doi: 10.1021/acs.jmedchem.0c00223
|
[36] |
DONG Y, ZHAO T, AI W, et al. Novel urate transporter 1(URAT1) inhibitors: A review of recent patent literature(2016-2019)[J]. Expert Opinion on Therapeutic Patents,2019,29(11):871−879. doi: 10.1080/13543776.2019.1676727
|